| Bioactivity | 6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity[1]. |
| CAS | 2702965-27-1 |
| Formula | C26H33ClFN9O |
| Molar Mass | 542.05 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chang C P, et al. Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus[J]. Molecular Cancer Therapeutics, 2024. |
6K465
CAS: 2702965-27-1 F: C26H33ClFN9O W: 542.05
6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, dem
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.